• Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams

  • Nov 7 2024
  • Length: 21 mins
  • Podcast

Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams

Listen for free

View show details

  • Summary

  • We love to hear from our listeners. Send us a message.

    On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Dennis Williams, Senior Vice President of Late Stage Development at Adaptimmune. Williams shares valuable insights into the groundbreaking world of TCR T-cell therapies, with a particular focus on the TECELRA trial. The trial led to the FDA approval of Tecelra, marking a significant milestone as the first engineered T-cell therapy for solid tumors. Williams delves into the complexities of developing this innovative treatment for synovial sarcoma, a rare and aggressive form of soft-tissue cancer. He also highlights the unique challenges and promising outcomes associated with TCR T-cell therapies, offering a comprehensive understanding of this cutting-edge approach in cancer immunotherapy.

    Subscribe to the podcast!
    Apple | Spotify | YouTube
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available